Bulger Eileen M, Hoyt David B
Department of Surgery, Harborview Medical Center, University of Washington, Box 359796, 325 9th Avenue, Seattle, WA 98104, USA.
Adv Surg. 2012;46:73-85. doi: 10.1016/j.yasu.2012.03.001.
There is a wealth of preclinical data suggesting potential benefit from the administration of hypertonic solutions after severe injury with hypovolemic shock, including improved tissue perfusion, improved flow through the microcirculation, and modulation of the inflammatory response, which may mitigate subsequent organ failure. However, despite these potential advantages, clinical trials of hypertonic resuscitation early after injury have failed to demonstrate significant benefit for resuscitation of hemorrhagic shock, and although there is no difference in overall mortality, there appears to be a trend toward earlier mortality among those receiving hypertonic fluids. Likewise, for TBI there are data suggesting that hypertonic fluids should support cerebral perfusion and mitigate intracranial hypertension, yet the clinical trials of early administration to these patients have also failed to show benefit. Further study is warranted in this patient population, as a longer period of hypertonicity may be required to show a clinical effect. Assessment of long-term neurologic outcome in this patient population remains the gold standard in determining benefit.
有大量临床前数据表明,在严重创伤合并低血容量性休克后给予高渗溶液可能有益,包括改善组织灌注、改善微循环血流以及调节炎症反应,这可能减轻随后的器官衰竭。然而,尽管有这些潜在优势,但创伤后早期高渗复苏的临床试验未能证明对失血性休克复苏有显著益处,并且尽管总体死亡率没有差异,但接受高渗液的患者似乎有更早死亡的趋势。同样,对于创伤性脑损伤,有数据表明高渗液应能支持脑灌注并减轻颅内高压,但对这些患者早期给药的临床试验也未能显示出益处。该患者群体有必要进行进一步研究,因为可能需要更长时间的高渗状态才能显示出临床效果。评估该患者群体的长期神经学结局仍然是确定益处的金标准。